Form D · Private Equity Fund
NGEN-Enzy LP
New York, NY · CIK 0002005822
Offering snapshot reported Sep 3, 2024 · SEC filing
- Reported sold
- $21.6M Indefinite offering
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 4, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
- Reported investors0 → 7
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 3, 2024 | Amendment | $21,554,508 | No comparison | 7 | SEC filing |
| Dec 27, 2023 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Pooled investment fund
- Exemptions
- 06b, 3C, 3C.7
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-500867
Source: Form D, filed Sep 3, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Grubstein | Executive |
| Shay Murphy | Executive |
| N/A Ngen Enzymedica Llc | Director |
| Rosemary Ripley | Executive |
Issuer details
Industry: Pooled Investment Fund (See others in industry)
Address:
C/O Ngen Enzymedica Llc 775 Park Avenue, #7 D
New York, NY, 10021
New York, NY, 10021